The Fund invested in BioVersys AG, page-6

johnmartin, The Fund estimated that the value of perhaps 10 % of BioVersys AG is 32,6 million CHF. BV 100 has just passed phase 1 and BV200 and BV300 are in the preclinical stages. In June they got 24.2M CHF financing also by issuing the same C series shares as now the Fond is doing.

PBT2 is the only drug, I know of, which prevents the development of antibiotic resistance. Over 30 different antibiotics can become effective again after losing their efficacy if combined with PBT2. Maybe BV100 will be one new antibiotic on this list. BV100 is developed from rifampicin and rifampicin-resistant tuberculosis is common. Of course, BV100 may be different and I hope it will be because tuberculosis is such difficult to treat. I do not know if Rifampicin was ever tested by QU microbiologists together with PBT2.

The fund was planning to invest after the 4th of April 2022 announcement of some100M in 2022 but no further deals were made last year. With these 32,6M, there is still left to do a PBT2 deal with the old and perhaps new 2023 money. But it seems to be difficult to find the solution when ATH does not want to be an antibiotic company but only a neurodegeneration company. I think that the solution is a new antibiotic company owned mostly by ATH and a smaller share by the fund, which will then make Big Pharma deals ( different territories, different antibiotics, etc) all around the world.